Can ticagrelor be administered as a 90 mg once‑daily dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No – Ticagrelor 90 mg Once Daily is Not the Approved Dosing Regimen

Ticagrelor must be administered as 90 mg twice daily (BID), not once daily, for the treatment of acute coronary syndromes (ACS) and chronic coronary syndrome (CCS). This twice-daily dosing is consistently specified across all major guidelines and is the FDA-approved regimen 1, 2, 1, 3, 4, 5.

Standard Approved Dosing

The established dosing for ticagrelor is:

  • Loading dose: 180 mg orally
  • Maintenance dose: 90 mg orally twice daily 1, 2, 5

This applies to both:

  • NSTE-ACS patients (invasive or conservative strategy) 1, 2
  • STEMI patients managed with primary PCI 5
  • Post-PCI patients receiving coronary stents 2

The recommended maintenance dose of aspirin to be used with ticagrelor is specifically 81 mg daily (not higher doses) 1, 2, 1, 3, 4, 5.

Why Twice-Daily Dosing Matters

Pharmacokinetic Rationale

Ticagrelor is a reversible P2Y12 receptor inhibitor with specific pharmacokinetic properties that necessitate twice-daily dosing 1, 3, 4:

  • Rapid absorption: Median time to maximum concentration (Tmax) is 1.5-3 hours 6
  • Mean elimination half-life: 10.9-14.9 hours 7
  • Active parent compound: No biotransformation required for P2Y12 receptor inhibition 1, 3, 4

Pharmacodynamic Evidence

Research demonstrates that twice-daily dosing provides superior and more consistent platelet inhibition compared to once-daily regimens 6:

  • Studies in healthy volunteers showed that inhibition of platelet aggregation (IPA) was greater and better sustained at high levels with twice-daily versus once-daily regimens 6
  • Once-daily dosing resulted in large diurnal variation in platelet inhibition 8
  • At trough concentrations (lowest drug levels), once-daily dosing showed inadequate platelet inhibition compared to twice-daily dosing 6

Evidence from Low-Dose Studies

While some research has explored lower doses of ticagrelor (including 90 mg once daily), these studies were:

  1. Pharmacodynamic studies only – not clinical outcome trials 9, 8
  2. Conducted in specific populations (Asian patients, healthy volunteers) 9, 8, 7
  3. Not approved by regulatory agencies for clinical use
  4. Showed concerning variability in platelet inhibition with once-daily dosing 8

One study specifically noted that "due to a large diurnal variation occurring with a single daily dose, a lower dose twice-daily could be a better option" 8.

Clinical Implications

For ACS Patients

The evidence-based regimen that demonstrated mortality and morbidity benefit in the landmark PLATO trial was ticagrelor 90 mg twice daily 2, 10. This dosing:

  • Reduced cardiovascular death compared to clopidogrel 10
  • Reduced nonfatal myocardial infarction 10
  • Reduced stent thrombosis 5
  • Reduced overall mortality 10

Bleeding Risk Considerations

While ticagrelor 90 mg BID does increase bleeding risk compared to clopidogrel:

  • Non-CABG bleeding is higher with ticagrelor 1, 4
  • Intracranial bleeding was more common with ticagrelor 10
  • However, major bleeding rates were not significantly different from clopidogrel in the PLATO trial 10

If bleeding risk is a concern, the appropriate strategy is NOT to use once-daily dosing, but rather:

  • Consider de-escalation to clopidogrel 75 mg daily 11
  • Shorten duration of dual antiplatelet therapy 12
  • Use a lower approved dose (60 mg BID in specific populations, not 90 mg once daily) 13

Special Populations

Reduced Dose Option (60 mg BID)

There is one approved lower-dose regimen: ticagrelor 60 mg twice daily (not once daily), which is used for:

  • Extended secondary prevention beyond 12 months in patients with prior MI 12
  • This is still twice-daily dosing, maintaining the pharmacokinetic principle

Switching Scenarios

When switching between P2Y12 inhibitors 11:

  • From clopidogrel to ticagrelor: Give 180 mg loading dose followed by 90 mg BID 11
  • From prasugrel to ticagrelor: Give 90 mg BID without loading dose 11

All switching protocols maintain the twice-daily maintenance dosing.

Common Pitfalls to Avoid

  1. Do not prescribe ticagrelor 90 mg once daily – this is not an approved regimen and lacks clinical outcome data
  2. Do not confuse ticagrelor with clopidogrel dosing – clopidogrel is once daily; ticagrelor is twice daily
  3. Do not reduce aspirin dose below 75 mg or increase above 100 mg when using ticagrelor 5, 12
  4. Do not use ticagrelor in patients with prior stroke/TIA (prasugrel is contraindicated; consider clopidogrel instead) 2, 5

Summary Algorithm

For any patient requiring ticagrelor:

  • ✓ Loading dose: 180 mg orally
  • ✓ Maintenance: 90 mg orally twice daily
  • ✓ Aspirin: 75-100 mg once daily
  • ✓ Duration: Up to 12 months for ACS/post-PCI 1, 2, 5

If twice-daily dosing is problematic:

  • Consider clopidogrel 75 mg once daily instead 11
  • Address adherence barriers
  • Do NOT improvise with once-daily ticagrelor dosing

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.